Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. 
        		 
                    		   Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, Lu Y, Goodings C, Lin TN, Zhang R, Moriyama T, Yin Z, Li Z, Quah TC, Ariffin H, Tan AM, Shen S, Bhojwani D, Hu S, Chen S, Zheng H, Pui CH, Yeoh AE, Yang JJ. 
        		              
                         Genome Res 
                         27 :
                    		 2017 
                    		 185-195 
                        
                       
                    		   75 
        	              
                   
                     
                       
                         Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia. 
        		 
                    		   Ngoc PCT, Tan SH, Tan TK, Chan MM, Li Z, Yeoh AEJ, Tenen DG, Sanda T. 
        		              
                         Leukemia 
                         32 :
                    		 2018 
                    		 2138-2151 
                        
                       
                    		   31 
        	              
                   
                     
                       
                         Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. 
        		 
                    		   Lao ZT, Ding LW, An O, Hattori N, Sun QY, Tan KT, Mayakonda A, Chuan WG, Madan V, Lin DC, Yang H, Koeffler HP. 
        		              
                         Haematologica 
                         104 :
                    		 2019 
                    		 e200-e203 
                        
                       
                    		   6 
        	              
                   
                     
                       
                         The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer.  
        		 
                    		   Patel MB, Wang J. 
        		              
                         High Throughput 
                         8 :
                    		 2018 
                    		 E1 
                        
                       
                    		   4 
        	              
                   
                     
                       
                         RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. 
        		 
                    		   Koschut D, Ray D, Li Z, Giarin E, Groet J, Alić I, Kham SK, Chng WJ, Ariffin H, Weinstock DM, Yeoh AE, Basso G, Nižetić D. 
        		              
                         Oncogene 
                         40 :
                    		 2021 
                    		 746-762 
                        
                       
                    		   5 
        	              
                   
                     
                       
                         Short H2A histone variants are expressed in cancer. 
        		 
                    		   Chew GL, Bleakley M, Bradley RK, Malik HS, Henikoff S, Molaro A, Sarthy J. 
        		              
                         Nat Commun 
                         12 :
                    		 2021 
                    		 490 
                        
                       
                    		   21 
        	              
                   
                     
                       
                         Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. 
        		 
                    		   Li Z, Lee SHR, Chin WHN, Lu Y, Jiang N, Lim EH, Coustan-Smith E, Chiew KH, Oh BLZ, Koh GS, Chen Z, Kham SKY, Quah TC, Lin HP, Tan AM, Ariffin H, Yang JJ, Yeoh AE. 
        		              
                         Blood Adv 
                         5 :
                    		 2021 
                    		 5226-5238 
                        
                       
                    		   16 
        	              
                   
                     
                       
                         Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. 
        		 
                    		   Zhao X, Wang P, Diedrich JD, Smart B, Reyes N, Yoshimura S, Zhang J, Yang W, Barnett K, Xu B, Li Z, Huang X, Yu J, Crews K, Yeoh AEJ, Konopleva M, Wei CL, Pui CH, Savic D, Yang JJ. 
        		              
                         Nat Commun 
                         13 :
                    		 2022 
                    		 5401 
                        
                       
                    		   5 
        	              
                   
                     
                       
                         USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia via PLK1/LDHA axis. 
        		 
                    		   Liu S, Xiang Y, Wang B, Gao C, Chen Z, Xie S, Wu J, Liu Y, Zhao X, Yang C, Yue Z, Wang L, Wen X, Zhang R, Zhang F, Xu H, Zhai X, Zheng H, Zhang H, Qian M. 
        		              
                         Blood Adv 
                         7 :
                    		 2023 
                    		 3099-3112 
                        
                       
                    		   1 
        	              
                   
                     
                       
                         TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data. 
        		 
                    		   Gu A, Schmidt B, Lonsdale A, Jalaldeen R, Kosasih HJ, Brown LM, Sadras T, Ekert PG, Oshlack A. 
        		              
                         Blood Adv 
                         7 :
                    		 2023 
                    		 7402-7406 
                        
                       
                    		   0 
        	              
                   
                     
                       
                         DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers. 
        		 
                    		   Pineda JMB, Bradley RK. 
        		              
                         Elife 
                         12 :
                    		 2024 
                    		 RP89017 
                        
                       
                    		   1